Implementation of Non-Invasive Quantitative Ultrasound in Clinical Cancer Imaging.

Simple Summary: At present, quantitative ultrasound (QUS) is increasingly utilized in cancer imaging. Compared to other imaging modalities that take several days to weeks to assess treatment effectiveness, QUS can provide a rapid treatment evaluation. Its implementation has been documented in characterizing benign versus malignant breast lesions, assessing lymph nodes, predicting and monitoring tumor response, etc. Both preclinical and clinical studies have confirmed that changes in QUS parameters are directly correlated with tissue microstructural alterations. QUS parameters and textural analyses have widely been used to predict and monitor neoadjuvant chemotherapy (NAC) response in locally advanced breast cancer (LABC) patients. Thus, QUS methods have emerged as one of the most useful imaging techniques for the management of several tumor types. Quantitative ultrasound (QUS) is a non-invasive novel technique that allows treatment response monitoring. Studies have shown that QUS backscatter variables strongly correlate with changes observed microscopically. Increases in cell death result in significant alterations in ultrasound backscatter parameters. In particular, the parameters related to scatterer size and scatterer concentration tend to increase in relation to cell death. The use of QUS in monitoring tumor response has been discussed in several preclinical and clinical studies. Most of the preclinical studies have utilized QUS for evaluating cell death response by differentiating between viable cells and dead cells. In addition, clinical studies have incorporated QUS mostly for tissue characterization, including classifying benign versus malignant breast lesions, as well as responder versus non-responder patients. In this review, we highlight some of the important findings of previous preclinical and clinical studies and expand the applicability and therapeutic benefits of QUS in clinical settings. We summarized some recent clinical research advances in ultrasound-based radiomics analysis for monitoring and predicting treatment response and characterizing benign and malignant breast lesions. We also discuss current challenges, limitations, and future prospects of QUS-radiomics. [ABSTRACT FROM AUTHOR]